home / stock / gud:cc / gud:cc news

GUD:CC News and Press, Knight Therapeutics Inc.

Stock Information
Company Name: Knight Therapeutics Inc.
Stock Symbol: GUD:CC
Market: TSXC
Website: gud-knight.com
Menu
GUD:CC GUD:CC Quote GUD:CC Short GUD:CC News GUD:CC Articles GUD:CC Message Board
Get GUD:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
GUD:CC - Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

MONTREAL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian he...
GUD:CC - 5 Best-performing Canadian Pharma Stocks (Updated January 2026)

2026-01-05 16:10:00 ET From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic. Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies su...

GUD:CC - Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris

MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved  WYNZORA ® , a white uniform cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg...

GUD:CC - Knight Therapeutics Reports Third Quarter 2025 Results

Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or ...
GUD:CC - Expected Canadian Company Earnings on Thursday, November 6th, 2025

Lundin Gold Inc. (LUG:CA) is expected to report $1.05 for Q3 2025 ARC Resources Ltd. (ARX:CA) is expected to report $0.57 for Q3 2025 WELL Health Technologies Corp. (WELL:CA) is expected to report $0.03 for Q3 2025 Lassonde Industries Inc. Class A Subordinate Voting Shares (LAS.A:CA) ...

GUD:CC - Knight Announces Closing of US$100 Million Revolving Credit Facility

MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has closed the syndication of its US$100 million secured revolving credit facility (“t...

GUD:CC - Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylphenidate HCI extended-release capsules) in Canada. JORNAY PM™ is an extended-release...
GUD:CC - Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2025 financial results on Thursday, November 6, 2025 prior to market opening. Following the release, K...

GUD:CC - Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory approval and has launched MINJUVI® in Argentina...

GUD:CC - Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE ® (relugolix/estradiol/norethindrone acetate) in Canada. In June 2024, ...
Next 10